sNhaUMSHRANSHVA

aTShVRhNsUhV
foD T T ToQ Q o o o TQ o
u Rmod DQ moQ RogTQ o, T Q ToRQ Q

d T Q TRo

e tRkm t t t t
uQ DoB dQ T oBt
m maGMm B / rr

PT o T TQ TRo tQ To oHT
/MalGaYlYs /MalGaYlYs
 i i i

l l
, u LI u A uq R- A u QAuB -- 1q xu AR q m

ymuN m yAR q PIxAuN

ar d p m mW R af

ay G mx P ml L ac

af e p R m ml p mgp p at

ao x mI R Lp ry

aD I R rf

ac ipPmI

W Rp
8 vQq uq uI uA-AR qRI--3uxA A I A u A uI uq u uI 8 w I-3 q u A u QAuI IRQA uz- uA uA uI uWA--
z q AuB uLA qRI-uI 0qRAm gAq xu. A2u• A q Iq Au I IruqBu A A ruI u q A

8 WQq-AuB -- 1q xu QAu AR LLA Iq ru -AI AuzAuRI AB - I I-3 q u A ruqBu A A m

BuI 3uI--A xqA u uq -A I RA m 8 vI IutLxuq u u-qIz-AuB uI 3u q AR ruq q AR ru ARqI-r

8 .Bu3 uI Au Ax I u u-IR I q xru LAu Bu QA R A A qI-ru u QA u ILIxA muvQq u A uRI uzA

AR LLA Iq uI uI I-34A uq B LI q uq u QAuuuuu A uB uI 3uLA qR s-AxI-u A muPI qI-u A Rq

yLI uTA uLI3u u q AR -3uI -3u u3 muP-AI A Bu QAu A u A - uq u u A Lq A muw- ruvwvwutLxuSIz uq
R - uIu R u AxI q xu3 uA uA - uI uA qz-AuB uI 3uLq q A AIq u uLq Au Bu QA
AR LLA Iq m q B LI q m7
 ^RV73UVi', ,RV3iA4iFA<<31V7AU
-dfrur,, uomR.mli

d
D hc ho S hu
B R R Rrc R rd ru a rB Rt r rc k ryR ho haFmhy

N67ki7kiRUi3<31VOAU71R<< i53U3ORV32ikK==RO iA4iV63iRVVR1632iO3GAOVli'Vi7kiR2 7k32iVAiO3R2iV67kikK==RO i7Ui1AU8KU1V7AUi 7V6iV63

RVVR1632iO3GAOViRU2iVAi1AOO3<RV3i7Vi1<7U71R<< li)AOiV63iVO3U2kik31V7AUfiV63iAKViA4iORU53i R<K3kiRO3i6756<756V32i 7V6iO3kG31ViVAiV63
07AiO343O3U13iORU53iA4iO3kG31V7 3iO3GAOVkl

gP9 /EU4P AP9 3 t/uomR.mli d26a/APOa/c5 P8 U3 g8P5+9/D)AOi<RkViV6O33iV3kVko

s V Vpk hps 0 ,RV3ih ,RV3is ,RV3ir

3=A5<A07U hyldiiiii5c2/ hslTiCihglT

AdC oaliiiiii=7<7c1Kl== rlmiCiylm
FN yslyiiiiie rdiCiyd
C) IRaIiiiii4i/ mriCihTh
AVFNC) uia.iiiiie hhldiCihylT
g6 U3/yP z6z P/C6 5 uRaliiiiiihTSrc / yiCihT
-3KVOAG67<k gglriiiiie yTiCimT
/ =G6A1 V3k rhlhiiiiie sTiCiyT
LAUA1 V3k dlyiiiiie siCihT
D6925671239 .aoiiiiie hiCid
wRkAG67<k Tluiiiiie TiCis
vS963 P/y 4716z P
C6 5 ,auIiiiiihTSrc / hiCir

vS963 P/D692567123/C6 5 Ra.fiiiiihTSrc / TlTsiCiTlg

^<RV3<3ViFAKUV smpiiiiihTSrc / hgTiCiyhT

P M M 2p M V
E3i2AUIVi6R 3iRU iA4i AKO
(O V6OA1 V3iµ327=3UVRV7AU GO3 7AKki<R0iO3kK<Vki4AO
miiiii==c6AKO .visT
ÂRV3
V63k3iV3kVki7UiAKOiO31AO2k
P pv 0h V

'OAUiµ3OK= du
iiiii 5c2/ gTiCihuT
NAVR<i'OAUiw7U27U5iFRGR17V
DN'wFo rsmlrm
iiiii 5c2/ sgTiCiyTT

S M V V pT V

-3 z69 3U P+/LP46036S25
TLSvuze .a.iiiiie yiCigld

-3 z69P/N/WU9 250 ulRiiiii=5c2/ uTiCipp

Page 3/13
 ^RV73UVi', ,RV3iA4iFA<<31V7AU
-dfrur,, uomR.mli

d
D hc ho S hu
B R R Rrc R rd ru a rB Rt r rc k ryR ho haFmhy

N67ki7kiRUi3<31VOAU71R<< i53U3ORV32ikK==RO iA4iV63iRVVR1632iO3GAOVli'Vi7kiR2 7k32iVAiO3R2iV67kikK==RO i7Ui1AU8KU1V7AUi 7V6iV63

RVVR1632iO3GAOViRU2iVAi1AOO3<RV3i7Vi1<7U71R<< li)AOiV63iVO3U2kik31V7AUfiV63iAKViA4iORU53i R<K3kiRO3i6756<756V32i 7V6iO3kG31ViVAiV63
07AiO343O3U13iORU53iA4iO3kG31V7 3iO3GAOVkl

gP9 /EU4P AP9 3 t/uomR.mli d26a/APOa/c5 P8 U3 g8P5+9/D)AOi<RkViV6O33iV3kVko

K h V2pi0 H pUV ,RV3ih ,RV3is ,RV3ir

d366+/(8PU/E2 860P5 riiiii=5c2/ plmiCisTlh

(8PU ural.iiiii=5c2/ sTlpiCiyrlT
FO3RV7U7U3 Tlgpiiiii=5c2/ TlgiCihls
MO71ij172 ylmiiiii=5c2/ slgiCidls
µA27K= hyTiiiii==A<c/ hrdiCihyg
^AVRkk7K= rlmiiiii==A<c/ rlgiCiglh

F hpT V

F6A<3kV3OA<iCiNAVR< hgdiiiii=5c2/ gTiCisTT

g8203 zP82+P9 li.iiiii=5c2/ TiCihgT
F6A<3kV3OA<iCi ,/ yT
iiiii=5c2/ yTiCidT
F6A<3kV3OA<iCi/,/ ddlmiiiii=5c2/ yTiCihTT
C163P9 P863N/)yVy iraliiiii=5c2/ hTiCirT
-AUi ,/iF6A<3kV3OA< hhdiiiii=5c2/ TiCihrT

F 1V pi0 H pUV

w7<7OK07UiCiNAVR< Tlriiiii=5c2/ TlriCihls E3i2AUIVi6R 3iRU iA4i AKO

^OAV37UfiNAVR< uldiiiii5c2/ dlsiCimlh GO3 7AKki<R0iO3kK<Vki4AO
j<0K=7U yldiiiii5c2/ rlsiCiyld V63k3iV3kVki7UiAKOiO31AO2k
jkGROVRV3iNORUkR=7URk3
DµW%No sd
iiiiiMc/ giCiry

j<RU7U3iNORUkR=7URk3
DµW^No sm
iiiiiMc/ TiCiry

j<9R<7U3i^6AkG6RVRk3 hhyiiiiiMc/ yTiCihgT

WR==R
ss
iiiiiMc/ piCirm
W<KVR= <VORUk43ORk3iDWWNo

R VpL 0 Vplpc H H 2

v77PU8U5zP H3201 3 /LUiiiiii F/(jÂ

Page 4/13
 ^RV73UVi', ,RV3iA4iFA<<31V7AU
-dfrur,, uomR.mli

d
D hc ho S hu
B R R Rrc R rd ru a rB Rt r rc k ryR ho haFmhy

N67ki7kiRUi3<31VOAU71R<< i53U3ORV32ikK==RO iA4iV63iRVVR1632iO3GAOVli'Vi7kiR2 7k32iVAiO3R2iV67kikK==RO i7Ui1AU8KU1V7AUi 7V6iV63

RVVR1632iO3GAOViRU2iVAi1AOO3<RV3i7Vi1<7U71R<< li)AOiV63iVO3U2kik31V7AUfiV63iAKViA4iORU53i R<K3kiRO3i6756<756V32i 7V6iO3kG31ViVAiV63
07AiO343O3U13iORU53iA4iO3kG31V7 3iO3GAOVkl

gP9 /EU4P AP9 3 t/uomR.mli d26a/APOa/c5 P8 U3 g8P5+9/D)AOi<RkViV6O33iV3kVko

R VpL 0 Vplpc H H 2 ,RV3ih ,RV3is ,RV3ir

µG317471i5OR 7V hlThg
iiiiii hlTTriCihlTrg
G dlTiiiiii yldiCim
W<K1Ak3 -35RV7 iiiiii
3 -(WjN'B(
^OAV37U -35RV7 iiiiii
3 -(WjN'B(
H3VAU3k -35RV7 iiiiii
3 -(WjN'B(
yP z6z P/D9 P8U9P usiiiiii -(WjN'B(
h 9/zP339 INuR
iiiiic6G4 TiCig
Â32i0<AA2i13<< -7<iiiiic6G4 TiCis
D72 1P32U3/zP339 oN.iiiiic6G4 )(E
FRkVk -7<iiiiic<G4 -'/
FO kVR<k -7<iiiiii -'/

sM H 0 pM hpk VpDVM

)2 U425/V/TloNpLe u,a.uiiiiiU5c=/ rTiCihTT

FR<17K= hTlhiiiii=5c2/ mlyiCihTls

& M pT V
E3i2AUIVi6R 3iRU iA4i AKO
B7VR=7Uiwhs rdpiiiiiG5c=< shhiCiphh
GO3 7AKki<R0iO3kK<Vki4AO
U 2 hpi0 H pUV V63k3iV3kVki7UiAKOiO31AO2k
NrfiNAVR< TlpmiiiiiU5c=/ TldTiCihlmh
git/g6 U3 ulafiiiii 5c2< ylgiCihsld
N6 OA72iµV7=K<RV7U5
AO=AU3iCiM<VORiµ3Uk7V7 3 slugm
iiiiiK'Mc=< TlggiCiylum

Page 5/13
 i i i

h
c L hg P Rhy RR R R
M k rh. . c rE r3 rv* C*. crM *2 hi R haFmhD

d fR

B*.cw v*.cw vk. eAM

t t t t t t t t

B*k rWc* eP
t t t t

W R hx

x.kC* * B3 * * . D * lSx
D 0*3r r k * r3* D 0*3r r k * r3* D 0*3r r k * r3* D 0*3r r k * r3*

x* * . W 2.* 3 D *
D 0*3r r k * r3* D 0*3r r k * r3* D 0*3r r k * r3*

IrH Ck r rkrC* * r3 rC3rV * . cr w*r1* C*. cr. *2mrB* *

I hWR R

i
t t t t

Page 6/13
 i i i

.<'
d 0 0hS M0M c hTM 0
.'<Pr <K'rx<P='363I(7U3rD7AU3'r.KAArf<2 rx6319K=rO7)6rDPE')rV3=<') hCM MhVlFhL

o M0Mhp &ho 1 0
H7U3(rEIr7I(756)r7I)<r)63r63EA)6r<4r0A<<2rEI2r0A<<2r13AA(rO6716rE'3r3((3I)7EAr)<r1E'' r<K)rUE'7<K(
0<27A r4KI1)7<I(rA793r)'EI(=<')7I5r< 53Ipr4756)7I5r7I431)7<I(prEI2r1A<))7I5r0A<<2rE4)3'rEIr7I8K' h

3P<5A<07I Vfx xW -xÂ

yzhe 5s2: NhHz P7A7s1KhPP zHhz m +th+ 4r:

VEI53arvShirervdhi VEI53arlhwrerBhw VEI53arlcrerBc VEI53arwlrerviv

V,µex W<)EAr:3K1<1 )3rx<KI) T3K)'<=67A( : P=6<1 )3(

yzhe m ythHz viNls : NNha m ayhy m

VEI53arvvhcrervBhi VEI53arBrervi VEI53arBirerwi VEI53arSirerBi

-<I<1 )3( j<(7I<=67A( fE(<=67A( g0(<AK)3r: P=6<1 )3rx<KI)

ehz m ehN m thv m ahy+ viNls :

VEI53arSrervi VEI53arvrerc VEI53arirerS VEI53arvrerl

g0(<AK)3rj<(7I<=67Arx<KI) MAE)3A3)rx<KI)
thev viNls : H+- viNls :

VEI53arihiSrerihd VEI53arvdirerBvi

d H 0 3h M
3A=(r)<rKI23'()EI2r='3(3I13r<4rEIr7I4AEPPE)7<Ir7Ir)63r0<2 hr/I4AEPPE)7<Ir7(r0<273(r2343I13
E5E7I()r7I431)7<Ir<'r7I8K' h

j' )6'<1 )3rD327P3I)E)7<IrVE)3

+ PPs6<K'

VEI53arRGrSi

Page 7/13
 i i i

.<'
d 0 0hS M0M c hTM 0
.'<Pr <K'rx<P='363I(7U3rD7AU3'r.KAArf<2 rx6319K=rO7)6rDPE')rV3=<') hCM MhVlFhL

d hD01& M
/'<Ir7(rErU7)EArP7I3'EAhr/)r63A=(r<K'r0A<<2r13AA(r)<r)'EI(=<')r< 53Ihr/'<Ir()K273(rE'3rK(32r)<rE((3((rA3U3A
<4r7'<Ir7Ir0A<<2rEI2r0A<<2y(rE07A7) r)<rE))E16r7)(3A4r)<r7'<Ihr

/'<IrD3'KP W<)EAr/'<Irf7I27I5rxE=E17) ruW/fxC

ev 5s2: aH+ha+ 5s2:

VEI53ardirervki VEI53arSdirerBii

P vM0M hS H M
-3E(K'3(r)63rA3U3Ar<4r5AK1<(3r7Ir)63r0<2 rEI2r63A=(r723I)74 r)63r0<2 y(rE07A7) r)<r='<13((r5AK1<(3hr/)
1EIr03rK(32r4<'r(1'3II7I5rE(rO3AArE(rP<I7)<'7I5r)63r)'3E)P3I)r<4r27E03)3(h

HA 1<( AE)32r 3P<5A<07Iru 0gv1C HAK1<(3rer.E()7I5

ehe m yHt P5s2:

VEI53arBrerdhc VEI53arkirertt

u & M3hC1 R0 hKM 0

M3'4<'P32r)<r23)3'P7I3r6<OrO3AAr)63r972I3 (rE'3rO<'97I5hrL72I3 (r'35KAE)3r3A7P7IE)7<Ir<4rOE()3r4'<P
<K'r0<2 rEI2rPE7I)E7Ir3A31)'<A )3r0EAEI13h

fA<<2r^'3ErT7)'<53I ^'3E x'3E)7I7I3 ^'71rg172

- P5s2: y-hHe P5s2: thN- P5s2: zh+ P5s2:

VEI53arthwrerSihv VEI53arSihtrerBlhi VEI53arihdrervhS VEI53arShdrerchS

D<27KP M<)E((7KP
yzt PP<As: ah+ PP<As:

VEI53arvlcrervBd VEI53arlhdrerdhv

Page 8/13
 i i i

.<'
d 0 0hS M0M c hTM 0
.'<Pr <K'rx<P='363I(7U3rD7AU3'r.KAArf<2 rx6319K=rO7)6rDPE')rV3=<') hCM MhVlFhL

f &hS H M
-3E(K'3(r)63rEP<KI)r<4rx6<A3()3'<ArEI2rW'75A 13'723(r7Ir <K'r0A<<2hrW67(r57U3(rEIr7I(756)r7I)<r)63
63EA)6r<4r63E')rEI2r0A<<2rU3((3A(hr

x6<A3()3'<ArerW<)EA W'75A 13'723( x6<A3()3'<Arer ,: x6<A3()3'<Arer:,:

yNe P5s2: Hze P5s2: zt P5s2: eeh+ P5s2:

VEI53ardirerSii VEI53arirervdi VEI53arBirerci VEI53arBirervii

x6<A3()3'<AerÂ:,: T<Ir ,:rx6<A3()3'<A

z-hH P5s2: yye P5s2:

VEI53arvirerli VEI53arirervli

f 2M hC1 R0 hKM 0
H'<K=r<4r0A<<2r)3()(r1<PP<IA r=3'4<'P32r)<r3UEAKE)3r)63r4KI1)7<Ir<4r)63rA7U3'rO6716r7(r3((3I)7EAr)<
2753()r4<<2rEI2r'3P<U7I5r)< 7I(r4'<Pr)63r0<2 h

f7A7'K07IrerW<)EA M'<)37IprW<)EA gA0KP7I

tha P5s2: vhe 5s2: zhe 5s2:

VEI53arihlrervhS VEI53archSrerwhv VEI53arlhSrerBhc

g(=E')E)3rW'EI(EP7IE(3ruDH%WC gAEI7I3rW'EI(EP7IE(3ruDHMWC
He ^s: H+ ^s:

VEI53ardrerlB VEI53arirerlB

gA9EA7I3rM6<(=6E)E(3 HEPPErHAK)EP A)'EI(43'E(3ruHHWC

yyz ^s: HH ^s:

VEI53arBirervdi VEI53artrerlw

Page 9/13
 i i i

.<'
d 0 0hS M0M c hTM 0
.'<Pr <K'rx<P='363I(7U3rD7AU3'r.KAArf<2 rx6319K=rO7)6rDPE')rV3=<') hCM MhVlFhL

c Mhi 10 Mhahy R R 3
-71'<(1<=71r3 EP7IE)7<Ir<4rK'7I3r(EP=A3r)<r16319r4<'r)63r='3(3I13r<4r0A<<2r13AA(pr1' ()EA(pr0E1)3'7Ep
=E'E(7)3(prEI2r13AA(r4'<Pr)KP<'(r7Ir7)h

g==3E'EI13 D=317471r5'EU7) = HAK1<(3

l r yhtyN r eht r r

VEI53arx:jgV VEI53arvhiilrervhild VEI53arBhcrerw VEI53arTjHgW/Âj

M'<)37I L3)<I3( :3K1<1 )3rj()3'E(3 MK(r13AA(

r r yi r +gyt s6=4

VEI53arTjHgW/Âj VEI53arTjHgW/Âj VEI53arTjHgW/Âj VEI53arirerd

V32r0A<<2r13AA j=7)63A7EAr13AA( xE()( x' ()EA(

s6=4 Nge s6=4 sA=4 r

VEI53arirerS VEI53ar.jµ VEI53arT/: VEI53arT/:

o R1 h &hp MhBM 0
-3E(K'3(r)63rA3U3A(r<4r1EA17KPrEI2rU7)EP7Ir,r7Ir)63r0A<<2rO6716rE'3r'3(=<I(70A3r4<'r933=7I5r0<I3(p
)33)6prEI2rPK(1A3(r63EA)6 hr

Â7)EP7Ir,ruSde% C xEA17KP
yahey I5sP: ythy P5s2:

VEI53arlirervii VEI53arwhBrervihS

Page 10/13
 i i i

.<'
d 0 0hS M0M c hTM 0
.'<Pr <K'rx<P='363I(7U3rD7AU3'r.KAArf<2 rx6319K=rO7)6rDPE')rV3=<') hCM MhVlFhL

T0 hS H M
Â7)EP7I(rE'3r)63r3((3I)7EArIK)'73I)(r4<'r6KPEIrA743hrW67(r='<47A3r<443'(r)3()(r)<r16319rA3U3Ar<4r27443'3I)
) =3(r<4rU7)EP7IrfprU7)EP7Ir,prU7)EP7IrjrEI2rU7)EP7IrLh

Â7)EP7IrfvS
ae- =5sPA

VEI53arSvvrertvv

K 3 &hC1 R0 hKM 0
µ7I2<Or)<r)63r63EA)6r<4r)63r0K))3'4A r(6E=32r5AEI2rerW6 '<72prO6716r23)3P7I3(r6<Or)63r0<2 rK(3(
3I3'5 h

WlprW<)EA WBprW<)EA
th-+ I5sP: yHhv 5s2A

VEI53arihcirervhwv VEI53arBhdrervShc

W6 '<72rD)7PKAE)7I5r <'P<I3rer^A)'ErD3I(7)7U3
HhvN+ K/^sPA

VEI53arihddrerBhkw

Page 11/13
 i i i

c
o f d fhi ff f f
hR f haFmhL
zS Ar rpA A r,ASx ,rS Ir0AxxpAT k

Yxc F2 - C - C

xc ' r0 aY 'Ftsc xapxc B x af am aM 2

r aI c2aY2 c x y rAS T kr0,A r2 r AAxr xxrS I
u T T T3Arx 0evSx TAr ASx rS I S TIrA 2T kr2 r xS Af
ST ST rSIA S Ar,2I S T r rS
,ASx ,TA rxT A 2xAf

- C - C I xx
u x D2am af ''x Mx as E F2' x x
qIA T 2r2 r TkkA r P TIrv,AvGT kr ,Ar T ArI T kr ,A
xAA xA A rS Ir 2r rS TIr ,A Tk, arT vx IT kr rSxS rvx vG rS I
,A rIA TvA fr.,T rvS rT v AS A
A SxrSv T T 2rS Ir SGArT r,S IA
r SxxrpSvGrS xAA f

L1x E x - C

S l aI c2aI c c 2aT S l af 2af aS af ap EF

B ' f aI
mA r rS Ir ArS IrA A 2 yA r ASxT TvrA1A vT Ark Sx rS I
ltedtr T A f k SI Sxx2rT v AS Ar2 rSv T T 2
xA Axr r S2r T S AIf

Page 12/13
 i i i

yzV
S]M]8]5I]9 .90GhP]52GBG8G4G5
hu]4G3]hrfRhQ89
yVz9rEV‘JE10rJz‘Vw1J

mF v9B14GB165h6MhFmk ]G8hCG8[16 G9I*3G8hd19]G9]haCPdVhS192

pmG3zJE5xzrIvrMVsr1ErK8dr:1x1VK8rwKV05z/KJw‘8KVrV5J7rLVz2581r2zVr‘J1r5xrLV59KV–rwKV1lrE41ryVK95x34K9rh1KVErME‘0–dk5Vw‘8KE5zxdrADD,
y1Qr'A.''StBulSigeRg

ml u8G415T0G4h(]G8Bh:B*[ oh( 7]8B]59165hS192

PKV574r)Hsr1ErK8drGrV5J7rJwzV1r2zVrLV105wE5x3rx1KVeE1V9r5xw501xw1rz2r4–L1VE1xJ5zxlrE41ryVK95x34K9rh1KVErME‘0–dGxxrHxE1Vxr(10d
ADD,.'i,tAul'DAe''Dd

m/ u8G4515T0G4h(]G8Bh:B*[ th:B862]hS192
p G3zJE5xzrIvsr1ErK8drMEVz71rV5J7rLVz2581lrK06‘JE91xEr2zVrKxE54–L1VE1xJ5/1r9105wKE5zxdr’41ryVK95x34K9rME‘0–drMEVz71d
'aai.ARt'uliDegd

mY d]78]99165ohHGB1]5Bh(]G3B0h *]9B1655G18]klhaH( klV

CVz1x71rCsr1ErK8dr’41rPKE51xErh1K8E4rN‘1JE5zxxK5V1eAlr/K8505E–rz2rKrEWze5E19r01LV1JJ5zxrJwV11x1Vd(10rkKV1drADDg.i't''ul'A,ie'AaAd

mR -5 1]B ohD]5]8G31 ][h-5 1]B hd1968[]8hlk1B]4haD-dklV

CVz1x71rCsr1ErK8drGxO51E–r05JzV01VJr5xrLV59KV–rwKV1lrLV1/K81xw1sr59LK5V91xEsrwz9zVQ505E–srKx0r01E1wE5zxdGxxrHxE1Vxr(10d
ADDS.'iBtRulg'SegARd

mf -5 1]B ohD]5]8G31 ][h-5 1]B hd1968[]8hck1B]4haD-dkcV

ML5E 1VrI;sr1ErK8drGrQV512r91KJ‘V1r2zVrKJJ1JJ5x3r31x1VK85 10rKxO51E–r05JzV01VlrE41r:GpeSdGVw4rHxE1Vxr(10drADDB.'BBl'DaAeSd

mc )5[1G5hd1Gz]B]9hS192h:I68]hA)dS:x
(z4Kxrjsr1ErK8drGrJ59L852510rHx05Kxrp5KQ1E1JrI5J7rMwzV1r2zVrJwV11x5x3r2zVr‘x05K3xzJ10r05KQ1E5wrJ‘Q61wEJdr rGJJzwrP4–J5w5KxJrHx05Kd
ADDR.RglSRaeSBgd

mE d1]BG8 hD*1[]315]9hM68h)5[1G59
p51EKV–r:‘50185x1Jr2zVrHx05KxJrerGr(Kx‘K8srM1wzx0rf05E5zxsrAD''dHk(Ie)KE5zxK8rHxJE5E‘E1rz2r)‘EV5E5zxsrh–01VKQK0d

mi g h73GB]hM68hB0]h[G
Idrh19K8KE4KdrPVz9zE5zxz2r (–rP8KE1r2zVrE41rpK– rKx0rL4–J5wK8rKwE5/5E–rK9zx3rE41rLzL‘8KE5zxrEzrLV1/1xErK88r2zV9Jrz2r9K8x‘EV5E5zx
Kx0r)kpJr5xrE41rwz‘xEV–srADAgdHk(Ie)KE5zxK8rHxJE5E‘E1rz2r)‘EV5E5zxsrh–01VKQK0d

Fm (]G3B0 hvGB15ThH3GB]
v‘5805x3rKrh1K8E4–rKx0rvK8Kxw10rp51E’41r)‘EV5E5zxrMz‘Vw1srp1LKVE91xErz2r)‘EV5E5zxsrhKV/KV0r’dhdrk4KxrMw4zz8rz2rP‘Q85wrh1K8E4d

FF p67hFmhpG2]k(64]hg]99GT]9hM68hB0]hH814G8 hH8] ]5B165h6MhCG8[16 G9I*3G8hd19]G9]

AD'arGkkcGhGr:‘50185x1rzxrE41rPV59KV–rPV1/1xE5zxrz2rkKV05z/KJw‘8KVrp5J1KJ1drk5Vw‘8KE5zxdrAD'arM1Lr'D.'iDt''ud

Fl :46215ThI]99GB165
G31e2V51x08–rPV59KV–rh1K8E4rkKV1rk1xEV1Jr’zz875EdrTzV80rh1K8E4r-V3Kx5 KE5zx

F/ :3]]7h( T1]5]
HV5J4r;Gsr1ErK8dr’41rVz81rz2rJ811Lr4–351x1r5xrLVz9zE5x3rL‘Q85wr41K8E4lrGrV1/51Wrz2r19L5V5wK8r1/501xw1drM811Lr(10rI1/drAD'R.AAlAgegBd

FY y6[ h4G99h15[] hayg)V

)‘EV5E5zxK8rMEKE‘Jrz2rTz91xrKx0r(1xsrAD'aeA'rHx05Kd)KE5zxK8ryK958–rh1K8E4rM‘V/1–rt)yhMrerRusrAD'a A'd

eeev5[h6Mh:4G8BhS]768Beee

Page 13/13
 P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815705 / 9820923 Sample Receive Date : 15/Jun/2024 10:04AM
Referred By : Dr. Report Status : Final Report
Sample Type : WHOLE BLOOD-EDTA Report Date : 15/Jun/2024 12:15PM

HAEMATOLOGY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method

Glycosylated Hemoglobin (HbA1c) 6.6 % 4-5.6 HPLC (NGSP certified)

Estimated average glucose (eAG) 142.72 mg/dL Calculated

Comment:
Interpretation: HbA1c%

≤5.6 Normal
5.7-6.4 At Risk For Diabetes
≥6.5 Diabetes

Adapted from American Diabetes Association.

Comments:
A 3 to 6 monthly monitoring is recommended in diabetics. People with diabetes should get the test done more often if their blood
sugar stays too high or if their healthcare provider makes any change in the treatment plan. HbA1c concentration represent the
integrated values for blood glucose over the preceding 8-12 weeks and is not affected by daily glucose fluctuation, exercise &
recent food intake.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions,
known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.

Factors that interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified
derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements.

Factors that affect interpretation of HbA1c Measurement: Any condition that shortens erythrocyte survival or decrease mean
erythrocyte age (e. g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test
results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c.

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the
HbA1c result does not correlate with the patient's blood glucose levels.

• HPLC - High performance liquid chromatography

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 1 of 16
P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815705 / 9820923 Sample Receive Date : 15/Jun/2024 10:04AM
Referred By : Dr. Report Status : Final Report
Sample Type : EDTA Report Date : 15/Jun/2024 12:16PM

HAEMATOLOGY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method

Complete Blood Count

Hemoglobin 14.6 g/dL 12.0 - 15.0 Cyanide-free SLS-
Hemoglobin
RBC 5.24 mili/cu.mm 3.8-4.8 DC Impedence Method
HCT 42.4 % 36 - 46 Pulse height average
MCV 80.8 fL 83 - 101 Calculated
MCH 27.9 pg 27 - 32 Calculated
MCHC 34.5 g/dL 31.5 - 34.5 Calculated
RDW-CV 14.6 % 11.6-14.0 Calculated
Total Leucocyte Count 10.24 10^3/µL 4 - 10 Impedence / Microscopy
Differential Leucocyte Count
Neutrophils 55.3 % 40-80 Double hydrodynamic
sequential
system/Microscopy
Lymphocytes 31.1 % 20-40 Flowcytometry DHSS/
Microscopy
Monocytes 6.4 % 2-10 Flowcytometry DHSS/
Microscopy
Eosinophils 6.5 % 1-6 Double hydrodynamic
sequential
system/Microscopy
Basophils 0.7 % 0-2 Double hydrodynamic
sequential
system/Microscopy
Absolute Leucocyte Count
Absolute Neutrophil Count 5.66 10^3/µL 2-7 Calculated
Absolute Lymphocyte Count 3.18 10^3/µL 1-3 Calculated
Absolute Monocyte Count 0.66 10^3/µL 0.2-1 Calculated
Absolute Eosinophil Count 0.67 10^3/µL 0.02-0.5 Calculated
Absolute Basophil Count 0.07 10^3/µL 0.02-0.1 Calculated
Platelet Count 289 10^3/µL 150-410 Impedence Variation
/Microscopy

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 2 of 16
 P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815705 / 9820923 Sample Receive Date : 15/Jun/2024 10:04AM
Referred By : Dr. Report Status : Final Report
Sample Type : EDTA Report Date : 15/Jun/2024 12:16PM

HAEMATOLOGY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method
MPV 8.5 fL 6.5 - 12 Calculated
PDW 13.7 fL 9-17 Calculated

Comment:
As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are
additionally being reported as absolute numbers of each cell in per unit volume of blood.

Erythrocyte Sedimentation Rate

Erythrocyte Sedimentation Rate 8 mm/hour <=20 Modified Westergren at
18C

Comment:

ESR provides an index of progress of the disease and is widely used as an indicator of inflammation, infection, trauma, or
malignant diseases. Changes are more significant than a single abnormal test
It is specifically indicated to monitor the course or response to the treatment of diseases like rheumatoid arthritis,
tuberculosis bacterial endocarditis ,acute rheumatic fever ,Hodgkins disease,temporal arthritis , and systemic lupus
erythematosis; and to diagnose and monitor giant cell arteritis and polymyalgia rheumatica.
An elevated ESR may also be associated with many other conditions, including autoimmune disease, anemia,
infection,malignancy,pregnancy, multiple myeloma, menstruation, and hypothyroidism.
Although a normal ESR cannot be taken to exclude the presence of organic disease, its rate is dependent on various
physiologic and pathologic factors.
The most important component influencing ESR is the composition of plasma. High level of C-Reactive Protein, fibrinogen,
haptoglobin, alpha-1antitrypsin, ceruloplasmin and immunoglobulins causes the elevation of Erythrocyte Sedimentation
Rate.
Drugs that may cause increase ESR levels include: dextran, methyldopa, oral contraceptives, penicillamine, procainamide,
theophylline, and Vitamin A. Drugs that may cause decrease levels include: aspirin, cortisone, and quinine

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 3 of 16
 P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815703 / 9820923 Sample Receive Date : 15/Jun/2024 09:53AM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 15/Jun/2024 11:39AM

BIOCHEMISTRY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method

Calcium
Calcium 10.1 mg/dL 8.4-10.2 Arsenazo III

Comment:
Increased in: Hyperparathyroidism primary and secondary, Acute and chronic renal failure, Following renal transplantation,
Osteomalacia with malabsorption, Acute osteoprosis, Malignant tumours (specially of breast, lung and kidney), Drugs: Vit. D and
A intoxication, Diuretics, estrogen, androgen, tamoxifen, lithium

Decreased in: Hypoparathyroidism, Surgical and Idiopathic, Pseudohypoparathyroidism, Chronic renal disease with uremia and
phophate retention, Malabsorption of Calcium and Vit.D, obstructive jaundice, Bone Disease ( Osteomalacia and rickets), Drugs:
Cancer chemotherapy drugs, calcitonin, loop-actives diuretics, Hypomagnesemia,Hypoalbuminemia

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 4 of 16
 P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815707 / 9820923 Sample Receive Date : 15/Jun/2024 09:56AM
Referred By : Dr. Report Status : Final Report
Sample Type : Fluoride Plasma F Report Date : 15/Jun/2024 11:39AM

BIOCHEMISTRY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method

Glucose - Fasting
Glucose - Fasting 120 mg/dL 70-99 Hexokinase/G-6-PDH

Fasting Plasma Glucose (mg/dL) 2 hr plasma Glucose (mg/dL) Diagnosis

99 or below 139 or below Normal
100 to 125 140 to 199 Pre-Diabetes (IGT)
126 or above 200 or above Diabetes

Reference : American Diabetes Association

Comment:
Impaired glucose tolerance (IGT) fasting, means a person has an increased risk of developing type 2 diabetes but does not
have it yet. A level of 126 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.
IGT (2 hrs Post meal ), means a person has an increased risk of developing type 2 diabetes but does not have it yet. A 2-hour
glucose level of 200 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes

Plasma Glucose Goals For people with Diabetes

Before meal 70-130 mg/dL
2 Hours after meal Less than 180 mg/dL
Less than 7%
HbA1c

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 5 of 16
 P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815703 / 9820923 Sample Receive Date : 15/Jun/2024 09:53AM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 15/Jun/2024 11:39AM

BIOCHEMISTRY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method

Iron Studies, Basic

Iron Serum 67 µg/dL 50-170 Ferene
Unsaturated Iron Binding Capacity 261 µg/dL 70 - 310 Ferrozine
Total Iron Binding Capacity ( TIBC) 328.38 µg/dL 250 - 400 Calculated
Transferrin Saturation 20.40 % 16-50 Calculated

Comment:

Iron is an essential trace mineral element which forms an important component of hemoglobin, metallocompounds and Vitamin
A. Deficiency of iron is seen in iron deficiency and anaemia of chronic disorders.
Increased iron concentration are seen in hemolytic anaemias, hemochromatosis and acute liver disease. Serum Iron alone is
unreliable due to considerable physiologic diurnal variation in the results with highest values in the morning and lowest values in
the evening as well as variation in response to iron therapy .

Total Iron Binding capacity (TIBC) is a direct measure of the protein Transferrin which transports iron from the gut to storage
sites in the bone marrow. Increased levels of TIBC suggest that total iron body stores are low, increased concentration may be
the sign of Iron deficiency anaemia, polycythemia vera ,and may occur during the third trimester of pregnancy. Decreased levels
may be seen in hemolytic anaemia, hemochromatosis, chronic liver disease, hypoproteinemia ,malnutrition.

Unsaturated Iron Binding Capacity (UIBC) is increased in low iron state and decreased in high iron concentration such as
hemochromatosis. In case of anaemia of chronic disease the patient may be anaemic but has adequate iron reserve and a low
uIBC.

Transferrin Saturation occurs in Idiopathic hemochromatosis and Transfusional hemosiderosis where no unsaturated iron
binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of Transferrin.

Lipid Profile
Cholesterol - Total 156 mg/dL Desirable <200, Enzymatic
Borderline High 200 -
239,
High >=240
Triglycerides 246 mg/dL Normal: < 150, Glycerol Phosphate
Borderline: 150 - 199, Oxidase
High:200 - 499,
Very High >=500
Cholesterol - HDL 40 mg/dL 40-60 Accelerator Selective
Detergent

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 6 of 16
 P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815703 / 9820923 Sample Receive Date : 15/Jun/2024 09:53AM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 15/Jun/2024 11:39AM

BIOCHEMISTRY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method
Cholesterol - LDL 67 mg/dL Desirable: <100 Calculated
Above desirable: 100 -
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 49 mg/dL 10 - 30 Calculated
Cholesterol : HDL Cholesterol 3.9 Ratio Desirable : 3.5-4.5 High Calculated
Risk : >5
LDL : HDL Cholesterol 1.67 Ratio Desirable : 2.5-3.0 High calculated
risk : >3.5
Non HDL Cholesterol 116 mg/dL Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,
Very High: >= 220

Comment:
•Lipid profile measurements in the same patient can show physiological & analytical variations. It is recommended that 3 serial
samples 1 week apart may be tested.
•Indians are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD); at a much earlier age and more severe
with high mortality. Dyslipidemia (abnormal lipid profile) is the major risk factor and found in almost 80% Indians.
•Total cholesterol is the total amount of cholesterol in blood comprising of HDL, LDL-C, and VLDL.
•LDL Cholesterol (LDL-C) or “bad”cholesterol contributes most significantly to atherosclerosis leading to heart disease or
stroke and is the primary target for reducing risk for cardiovascular disease.
•High-density lipoprotein (HDL) or “good” cholesterol can lower risk of heart disease and stroke.
•Triglyceride (TG) level also plays a major role in CVD. Indians are more prone to Atherogenic dyslipidemia, a condition
associated with high TG, low HDL-C and high LDL-C; this is associated with diabetes, metabolic syndrome and insulin resistance.
Hence high triglyceride levels also need to be treated.
•Non-HDL-Cholesterol (Non-HDLC) measures all plaque forming lipoproteins (e.g. remnants, LDL-C, VLDL, Lp(a), Apo-B).
Monitoring of Non-HDLC is important in patients with high TG (e.g. diabetics, obese persons) and those already on statin
therapy.
•Lipid Association of India (LAI-2020) recommends:-

Screening of all Indians above the age of 20 years for CVD risk factors, esp. lipid profile.
Identification of Risk factors: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age (<55 yrs

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 7 of 16
P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815703 / 9820923 Sample Receive Date : 15/Jun/2024 09:53AM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 15/Jun/2024 11:39AM

BIOCHEMISTRY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method
in males, <65 yrs in female), Smoking/tobacco use, High blood pressure, Low HDL (males <40 mg/dl and females
<50mg/dl).
Fasting lipid profile is not mandatory for screening. Both fasting and non-fasting lipid profiles are equally important for
managing Indian patients.
Non-HDLC should be calculated in every subject. LAI recommends LDL-C as the primary target and Non-HDLC as the co-
primary target for initiating drug therapy.
Lifestyle modifications are of first and foremost importance for management and prevention of dyslipidemia. Among low
risk groups, treatment is started only after 3 months of lifestyle changes.
Testing for Apolipoprotein B, hsCRP, Lp(a ) should be considered for patients in moderate risk group.
Newer treatment goals based on Risk Groups and values of LDL-C and Non-HDLC

New treatment goals by Lipid Association of India (2020)

CONSIDER THERAPY (cut-off level) TREATMENT GOALS
Risk groups LDL-C (mg/dL) Non-HDLC (mg/dL) LDL-C (mg/dL) Non-HDLC (mg/dL)
<50 <80
Extreme Risk Gp Cat. A ≥50 ≥80
(Optional ≤30) (Optional ≤60)
Extreme Risk Gp Cat. B >30 >60 ≤30 ≤60
Very High Risk ≥50 ≥80 <50 <80
High Risk ≥70 ≥100 <70 <100
Moderate Risk ≥100 ≥130 <100 <130
Low risk ≥130* ≥160* <100 <130
*After an adequate non-pharmacological intervention for at least 3 months

•As per NCEP Expert Panel (2011) guidelines, universal screening for dyslipidemia is recommended for children between 9
- 11 yrs (repeat at 17-21 yrs). Screening is not recommended before the age of 2yrs. Above the age of 2 yrs, selective screening
is done in children with family history of premature CVD or risk factors like obesity, diabetes, and hypertension.

Note: Reference Interval as per National Cholesterol Education Program (NCEP) Report.

Liver Function Test

Bilirubin-Total 0.30 mg/dL 0.3-1.2 Diazonium Salt
Bilirubin-Direct 0.14 mg/dL 0-0.5 Diazo
Bilirubin-Indirect 0.16 mg/dL 0 - 1.8 Calculated
Protein, Total 7.60 g/dL 6.2-8.1 Biuret
Albumin 4.60 g/dL 3.2-4.6 Bromocresol Green
Globulin 3.0 g/dl 1.8 - 3.6 Calculated
A/G Ratio 1.53 Ratio 0.8 - 1.9 Calculated

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 8 of 16
 P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815703 / 9820923 Sample Receive Date : 15/Jun/2024 09:53AM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 15/Jun/2024 11:39AM

BIOCHEMISTRY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method
Aspartate Transaminase (SGOT) 26 U/L 5-34 NADH w/o P-5’-P
Alanine Transaminase (SGPT) 28 U/L 0-34 NADH w/o P-5’-P
SGOT/SGPT 0.93 Ratio <1 Calculated
Alkaline Phosphatase 114 U/L 40-150 Para-Nitrophenyl
Phosphate
Gamma Glutamyltransferase (GGT) 22 U/L 9-38 L-gamma-glutamyl-3-
Carboxy-4-Nitroanilide

Comment:
Useful for screening liver damage in suspected infections, digestive disorders, alcohol intake or certain drugs.

Raised ALT, AST indicate hepatocellular disease. ALT (more liver-specific) activity higher than AST in acute or chronic viral
hepatitis, autoimmune, hemochromatosis, medications/toxins etc, while higher AST activity in alcoholic hepatitis,
cirrhosis and non-hepatic causes like hemolysis, myopathy, thyroid disease, exercise etc. SGOT/SGPT ratio >1 seen in
alcoholic cirrhosis, metastasis; high ratio in cirrhosis correlates with the grade of fibrosis.
Mild isolated raised ALT, AST (<2 times normal) levels may require only repeat testing; usually resolve in 1/3rd cases. Most
common cause in asymptomatic cases is Fatty liver disease esp. in patients with metabolic syndrome (MASLD). Some
drugs (like paracetamol, statins), herbal supplements, energy drinks, and antibiotics may cause liver injury.
Elevated alkaline phosphatase and GGT indicate cholestatic disease like bile duct obstruction, primary biliary cirrhosis,
primary sclerosing cholangitis or infiltrating diseases of the liver. Also high in other causes like bone disease, pregnancy,
CRF, malignancies, congestive heart failure etc.
High bilirubin indicates jaundice either due to RBC breakdown, liver damage by infections, toxins; or cholestasis due to gall
stones, tumors etc.
High protein levels seen in dehydration (inadequate intake or excessive water loss) in severe vomiting, diarrhea, etc or
increased production seen in inflammation, some hematopoietic neoplasms. Low protein and albumin seen in impaired
synthesis (liver disease) or decreased intake, tissue damage, malabsorption and increased renal excretion.

Kidney Function Test.

Blood Urea Nitrogen 9 mg/dL 9.8-20.1 Urease
Urea 19.26 mg/dL 20.9 - 43.0 Calculated
Creatinine 0.59 mg/dL 0.5-1.2 Kinetic Alkaline Picrate
Uric Acid 4.8 mg/dL 2.5-6.2 Uricase
Sodium 140 mmol/L 136-145 INDIRECT ISE

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 9 of 16
 P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815703 / 9820923 Sample Receive Date : 15/Jun/2024 09:53AM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 15/Jun/2024 11:39AM

BIOCHEMISTRY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method
Potassium 3.80 mmol/L 3.5-5.1 INDIRECT ISE
Chloride 105.0 mmol/L 98-107 INDIRECT ISE
BUN/Creatinine Ratio 15.2 Ratio 12:1 - 20:1 Calculated

Comment:
BUN is directly related to protein intake and nitrogen metabolism and inversely related to the rate of excretion of urea.Blood
urea nitrogen (BUN) levels reflect the balance between the production and excretion of urea. Increased levels are seen in renal
failure (acute or chronic), urinary tract obstruction, dehydration, shock, burns, CHF, GI bleeding, nephrotoxic drugs. Decreased
levels are seen in hepatic failure, nephrotic syndrome, cachexia (low-protein and high-carbohydrate diets).
Urea is a non-proteinous nitrogen compound formed in the liver from ammonia as an end product of protein metabolism. Urea
diffuses freely into extracellular and intracellular fluid and is ultimately excreted by the kidneys. Increased levels are found in
acute renal failure, chronic glomerulonephritis, congestive heart failure, decreased renal perfusion, diabetes, excessive protein
ingestion, gastrointestinal (GI) bleeding, hyperalimentation, hypovolemia, ketoacidosis, muscle wasting from starvation,
neoplasms, pyelonephritis, shock, urinary tract obstruction, nephrotoxic drugs. Decreased levels are seen in inadequate dietary
protein, low-protein/high-carbohydrate diet, malabsorption syndromes, pregnancy, severe liver disease, certain drugs.
Creatinine is catabolic product of creatinine phosphate, which is excreted by filtration through the glomerulus and by tubular
secretion. Creatinine clearance is an acceptable clinical measure of glomerular filtration rate (GFR). Increased levels are seen in
acute/chronic renal failure, urinary tract obstruction, hypothyroidism, nephrotoxic drugs, shock, dehydration, congestive heart
failure, diabetes. Decreased levels are found in muscular dystrophy.
BUN/Creatinine ratio (normally 12:1–20:1) is decreased in acute tubular necrosis, advanced liver disease, low protein intake,
and following hemodialysis. BUN/Creatinine ratio is increased in dehydration, GI bleeding, and increased catabolism.
Uric acid levels show diurnal variation. The level is usually higher in the morning and lower in the evening. Increased levels are
seen in starvation, strenuous exercise, malnutrition, or lead poisoning, gout, renal disorders, increased breakdown of body cells
in some cancers (including leukemia, lymphoma, and multiple myeloma) or cancer treatments, hemolytic anemia, sickle cell
anemia, or heart failure, pre-eclampsia, liver disease (cirrhosis), obesity, psoriasis, hypothyroidism, low blood levels of
parathyroid hormone (PTH), certain drugs, foods that are very high in purines - such as organ meats, red meats, some seafood
and beer. Decreased levels are seen in liver disease, Wilson's disease, Syndrome of inappropriate antidiuretic hormone (SIADH),
certain drugs.

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 10 of 16
P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815703 / 9820923 Sample Receive Date : 15/Jun/2024 09:53AM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 15/Jun/2024 03:03PM

Immunology
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method

Thyroid Profile
T3, Total 0.98 ng/mL 0.60-1.81 CLIA
T4, Total 12.7 µg/dl 4.5-12.6 CLIA
Thyroid Stimulating Hormone - Ultra 2.758 uIU/ml 0.55-4.78 CLIA
Sensitive

Comment:

Below mentioned are the guidelines for pregnancy related reference ranges for TSH, total T3 & Total T4.

Pregnancy
TSH (μIU/mL) (as per
American Thyroid Total T3 (ng/mL) Total T4(μg/dL)
Association )
1st trimester 0.1-2.5 0.81-1.90 7.33-14.8
2nd trimester 0.2-3.0 1.00-2.60 7.93-16.1
3rd trimester 0.3-3.0 1.00-2.60 6.95-15.7

TSH levels are subject to circadian variation, reaching peak levels between 2 - 4.a.m. and at a minimum between 6-10 pm
.
The variation is of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
TSH is secreted in a dual fashion: Intermittent pulses constitute 60-70% of total amount, background continuous secretion
is 30-40%.These pulses occur regularly every 1-3 hrs.
Total T3 & T4 concentrations are altered by physiological or pathological changes in thyroxine binding globulin (TBG)
capacity .
The determination of free T3 & free T4 has the advantage of being independent of changes in the concentrations and
binding properties of the binding proteins.
Changes in thyroid status are typically associated with concordant changes in T3, T4 and TSH levels.
Unexpectedly abnormal or discordant thyroid test values may be seen with some rare, but clinically significant conditions
such as central hypothyroidism, TSH-secreting pituitary tumors, thyroid hormone resistance, or the presence of
heterophilic antibodies (HAMA) or thyroid hormone autoantibodies.
For diagnostic purposes, results should be used in conjunction with other data.

TSH T3 T4 Interpretation

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 11 of 16
P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815703 / 9820923 Sample Receive Date : 15/Jun/2024 09:53AM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 15/Jun/2024 03:03PM

Immunology
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method
High Normal Normal Subclinical Hypothyroidism
Low Normal Normal Subclinical Hyperthyroidism
High High High Secondary Hyperthyroidism
Low High/Normal High/Normal Hyperthyroidism
Non thyroidal illness / Secondary
Low Low Low Hypothyroidism

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 12 of 16
 P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815703 / 9820923 Sample Receive Date : 15/Jun/2024 09:53AM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 15/Jun/2024 11:39AM

Immunology
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method

Vitamin D (25-OH)
Vitamin D (25-OH) 13.6 ng/mL Deficiency:< 20, CLIA
Insufficiency:20-29,
Sufficiency:30 - 100,
Toxicity possible:> 100

Comment:

Vitamin D is a fat-soluble steroid prohormone involved in the intestinal absorption of calcium and the regulation of calcium
homeostasis.
Two forms of vitamin D are biologically relevant - vitamin D3 (Cholecalciferol) and vitamin D2 (Ergocalciferol).
Both vitamins D3 and D2 can be absorbed from food but only an estimated 10-20perc. of vitamin D is supplied through
nutritional intake.
Vitamin D is converted to the active hormone 1,25-(OH)2-vitamin D (Calcitriol) through two hydroxylation reactions. The
first hydroxylation converts vitamin D into 25-OH vitamin D and occurs in the liver. The second hydroxylation converts 25-
OH vitamin D into the biologically active 1,25-(OH)2-vitamin D and occurs in the kidneys as well as in many other cells of
the body.
Most cells express the vitamin D receptor and about 3perc. of the human genome is directly or indirectly regulated by the
vitamin D endocrine system.
The major storage form of vitamin D is 25-OH vitamin D and is present in the blood at up to 1,000 fold higher
concentration compared to the active 1,25-(OH)2-vitamin D. 25-OH vitamin D has a half-life of 2-3 weeks vs. 4 hours for
1,25-(OH)2-vitamin D. Therefore, 25-OH vitamin D is the analyte of choice for determination of the vitamin D status.
Risk factors for vitamin D deficiency include low sun exposure, inadequate intake, decreased absorption, abnormal
metabolism, vitamin D resistance and and liver or kidney diseases.
Vitamin D deficiency is a cause of secondary hyperparathyroidism and diseases resulting in impaired bone metabolism (like
rickets, osteomalacia).
Recently, many chronic diseases such as cancer, high blood pressure, osteoporosis and several autoimmune diseases
have been linked to vitamin D deficiency.
The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D

Utility Quantitative determination of 25-hydroxyvitamin D (25-OH vitamin D).

Vitamin B12

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 13 of 16
P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815703 / 9820923 Sample Receive Date : 15/Jun/2024 09:53AM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 15/Jun/2024 11:39AM

Immunology
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method
Vitamin B12 369.0 pg/ml 211 - 911 CLIA

Comment:

Vitamin B12 along with folate is essential for DNA synthesis and myelin formation.
Decreased levels a r e s e e n i n a n a e m i a , t e r m p r e g n a n c y , v e g e t a r i a n d i e t , i n t r i n s i c f a c t o r d e f i c i e n c y , p a r t i a l
gastrectomy/ileal damage, celiac disease, oral contraceptive use, parasitic infestation, pancreatic deficiency, treated
epilepsy, smoking, hemodialysis and advanced age.
Increased levels are seen in renal failure, hepatocelluar disorders, myeloproliferative disorders and at times with excess
supplementation of vitamins pills.

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 14 of 16
 P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815709 / 9820923 Sample Receive Date : 15/Jun/2024 10:06AM
Referred By : Dr. Report Status : Final Report
Sample Type : Urine Report Date : 15/Jun/2024 12:24PM

CLINICAL PATHOLOGY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method

Urine Routine & Microscopy

Colour Pale Yellow Pale Yellow
Appearance Slightly Hazy Clear Visual
Specific gravity 1.015 1.003 - 1.035 pKa change
pH 6.0 4.6 - 8.0 Double Indicator
Glucose Negative Negative GOD-POD
Protein Negative Negative Protein Error Principle
Ketones Negative Negative Nitroprusside
Blood Negative Negative Peroxidase
Bilirubin Negative Negative Diazonium
Urobilinogen Normal Normal Ehrlich
Leucocyte Esterase 1+ Negative Pyrrole
Nitrite Negative Negative Diazonium Compound
Pus cells 8-10 /hpf 0-5 Microscopy
Red Blood Cells Nil /hpf 0-2 Microscopy
Epithelial cells 5-6 /hpf Few Microscopy
Casts Nil /lpf Nil Microscopy
Crystals Nil Nil Microscopy
Yeast Nil Nil Microscopy
Bacteria Nil Nil Microscopy

Comment:
•Note: Pre-test condition to be observed while submitting the sample-first void, mid stream urine, collected in a clean, dry, sterile
container is recommended for routine urine analysis, avoid contamination with any discharge from vaginal, urethra, perineum,
Avoid prolonged transit time & undue exposure to sunlight.
•During interpretation, points to be considered are Negative nitrite test does not exclude the urinary tract infections. Trace
proteinuria can be seen with many physiological conditions like prolonged recumbency, exercise, high protein diet. False positive
reactions for bile pigments, proteins, glucose and nitrites can be caused by peroxidase like activity by disinfectants, therapeutic
dyes, ascorbic acid and certain drugs.• Urine microscopy is done in centrifuged urine specimens

*** End Of Report ***

Conditions of Laboratory Testing & Reporting:

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 15 of 16
 P O No :P O 1140920007-249

Name : Ms.USHA VENKATARAMAN Client Name : TATA 1MG BANGALORE

Age/Gender : 65/Female Registration Date : 15/Jun/2024 09:44AM
Patient ID : MGB791933 Collection Date : 15/Jun/2024 06:34AM
Barcode ID/Order ID : D11815709 / 9820923 Sample Receive Date : 15/Jun/2024 10:06AM
Referred By : Dr. Report Status : Final Report
Sample Type : Urine Report Date : 15/Jun/2024 12:24PM

CLINICAL PATHOLOGY
COMPREHENSIVE SILVER FULL BODY CHECKUP WITH SMART REPORT
Test Name Result Unit Bio. Ref. Interval Method
Test results released pertain to the sample, as received. Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should
be clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report
may vary depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal
purposes. Please mail your queries related to test results to Customer Care mall ID care@1mg.com

Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All
lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes.
Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the
information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be
vetted by a qualified doctor only.

This test has been performed at

TATA 1MG BANGALORE
Address: No 607, Ground, 1st,2nd, & 3rd
Floor, 80 Feet Road, 6th Block, Koramangala,
Bengaluru, 560095

Page 16 of 16
 Ensuring accuracy IN every single report
Following a 3-step review process:

Advanced systems & Experienced lab experts Each report undergoes

cutting-edge technology analyze and technicians conduct rigorous medical scrutiny & is
results with precision comprehensive reviews signed off by a doctor

Have concerns regarding the report?

Reach out to our care team at care@1mg.com
or chat with us
CONNECT NOW >

Accurate Testing, Assured Quality: Diagnostics Precision

Stringent quality control Cutting-edge technology Experienced lab staff

Measures meeting Robust healthcare systems 30+ medical professionals
international norms of safety equipped with calibrated & with a collective
guidelines well-maintained machinery experience of 200+ years

Verified test procedures External assessments Trained phlebotomists

Highly standardized test Thorough third-party Ensuring smooth sample
procedures following CLSI* assessment by authorized collection experience &
guidelines experts pre-analytical precision

Claim FREE doctor consultation

Watch how
Consult top doctors from
the comfort of your home
we take care of
your sample
SCHEDULE NOW>

Get Second Opinion Order Medicines EXPLORE NOW >

Explore Financial Need Help?

Book Lab Tests
Support & more 1800-102-1618

*Clinical & Laboratory Standards Institute T&C Apply